In This Section

PCWG at the Annual Meeting

Virtual Meeting Week 1: April 10-15; Week 2: May 17-21

The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.

Be sure to watch the AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research on demand starting April 10th on our online meeting platform.

TM05. Pediatric Cancer Working Group (PCWG) Town Hall Meeting

Thursday, May 20, 2021, 3:30 pm – 5:00 pm
PCWG Chair Kimberly Stegmaier. Dana-Farber Cancer Institute, Boston, MA
PCWG Chair-Elect Katherine A. Janeway. Dana-Farber Cancer Institute, Boston, MA

Birgit Knoechel. Dana-Farber Cancer Institute, Boston, MA
Transcriptional heterogeneity reveals novel therapeutic vulnerabilities in T-ALL

Marielle Yohe. National Cancer Institute, MD
Targeting RAS signaling in pediatric solid tumors

REGSCI06. ACCELERATE-ing Pediatric Cancer Drug Discovery and Development

Thursday, May 20, 2021, 9:45 am – 11:15 am
Channel 03

The RACE for Children Act, incorporated as Title V Sec 504 of the FDA Reauthorization Act (FDARA), enacted on August 18, 2017, requires early pediatric assessment of new molecularly targeted drugs and biologics “intended for the treatment of adult cancers and directed at a molecular target substantially relevant to the growth or progression of a pediatric cancer.” All meeting attendees are encouraged to attend this special session whereby stakeholders from the AACR Pediatric Cancer Working Group, the ACCELERATE Innovation for Children and Adolescents with Cancer Platform, the U.S. Food and Drug Administration, European Medicines Agency, industry, academia, and pediatric cancer advocacy community will discuss the early implementation experience since the full activation of the RACE for Children Act on August 18, 2020. The early impact of the newly established legislative requirements on industry plans and strategies and discussion of potential metrics to assess the effect of the RACE for Children Act will also be explored. Session presentations will also focus on reviewing the potential global impact of the RACE for Children Act and the role of the ACCELERATE platform in facilitating collaborative opportunities to advance the development of innovative anticancer medicines for children.

Gregory H. Reaman. FDA-CDER, Silver Spring, MD
Lori Ehrlich. U.S. Food and Drug Administration, Silver Spring, MD
Mark W. Kieran. Bristol-Myers Squibb Co. – New York, NY, Lawrenceville, NJ
Gilles Vassal. Gustave Roussy, VIllejuif, France
Steven DuBois. Dana-Farber Cancer Institute, Boston, MA
Nancy F. Goodman. Kids v Cancer, Washington, DC
Martha Donoghue. U.S. Food and Drug Administration, Silver Spring, MD
Brenda J. Weigel. University of Minnesota, Minneapolis, MN
Andrew D J Pearson. ACCELERATE, London, United Kingdom
Scott J. Diede. Merck, North Wales, PA

See more on the online meeting planner.